A few pilot studies have explored the use of bromocriptine, a dopamine agonist, to treat adenomyosis by suppressing PRL production.45–47 However, activating dopamine signaling may alleviate adenomyosis symptoms via mechanisms other than attenuating PRL signaling.30 Moreover, in addition to adverse effects, some patients are resistant to bromocriptine treatment,48,49 limiting its therapeutic potential and suggesting that the source of PRL may be a critical factor. Here, PRL is linked to adenomyosis.